ID   USP9Y_HUMAN             Reviewed;        2555 AA.
AC   O00507; O14601;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 2.
DT   12-APR-2017, entry version 164.
DE   RecName: Full=Probable ubiquitin carboxyl-terminal hydrolase FAF-Y;
DE            EC=3.4.19.12;
DE   AltName: Full=Deubiquitinating enzyme FAF-Y;
DE   AltName: Full=Fat facets protein-related, Y-linked;
DE   AltName: Full=Ubiquitin thioesterase FAF-Y;
DE   AltName: Full=Ubiquitin-specific protease 9, Y chromosome;
DE   AltName: Full=Ubiquitin-specific-processing protease FAF-Y;
GN   Name=USP9Y; Synonyms=DFFRY;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Testis;
RX   PubMed=8922996; DOI=10.1093/hmg/5.11.1695;
RA   Jones M.H., Furlong R.A., Burkin H., Chalmers I.J., Brown G.M.,
RA   Khwaja O., Affara N.A.;
RT   "The Drosophila developmental gene fat facets has a human homologue in
RT   Xp11.4 which escapes X-inactivation and has related sequences on
RT   Yq11.2.";
RL   Hum. Mol. Genet. 5:1695-1701(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9381176; DOI=10.1126/science.278.5338.675;
RA   Lahn B.T., Page D.C.;
RT   "Functional coherence of the human Y chromosome.";
RL   Science 278:675-680(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], GENE MAPPING, AND VARIANT THR-1060.
RC   TISSUE=Fetal brain, Retina, and Testis;
RX   PubMed=9384609; DOI=10.1093/hmg/7.1.97;
RA   Brown G.M., Furlong R.A., Sargent C.A., Erickson R.P., Longepied G.,
RA   Mitchell M., Jones M.H., Hargreave T.B., Cooke H.J., Affara N.A.;
RT   "Characterisation of the coding sequence and fine mapping of the human
RT   DFFRY gene and comparative expression analysis and mapping to the Sxrb
RT   interval of the mouse Y chromosome of the Dffry gene.";
RL   Hum. Mol. Genet. 7:97-107(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12815422; DOI=10.1038/nature01722;
RA   Skaletsky H., Kuroda-Kawaguchi T., Minx P.J., Cordum H.S.,
RA   Hillier L.W., Brown L.G., Repping S., Pyntikova T., Ali J., Bieri T.,
RA   Chinwalla A., Delehaunty A., Delehaunty K., Du H., Fewell G.,
RA   Fulton L., Fulton R., Graves T.A., Hou S.-F., Latrielle P.,
RA   Leonard S., Mardis E., Maupin R., McPherson J., Miner T., Nash W.,
RA   Nguyen C., Ozersky P., Pepin K., Rock S., Rohlfing T., Scott K.,
RA   Schultz B., Strong C., Tin-Wollam A., Yang S.-P., Waterston R.H.,
RA   Wilson R.K., Rozen S., Page D.C.;
RT   "The male-specific region of the human Y chromosome is a mosaic of
RT   discrete sequence classes.";
RL   Nature 423:825-837(2003).
RN   [5]
RP   POSSIBLE INVOLVEMENT IN SPGFY2.
RX   PubMed=10581029; DOI=10.1038/70539;
RA   Sun C., Skaletsky H., Birren B., Devon K., Tang Z., Silber S.,
RA   Oates R., Page D.C.;
RT   "An azoospermic man with a de novo point mutation in the Y-chromosomal
RT   gene USP9Y.";
RL   Nat. Genet. 23:429-432(1999).
RN   [6]
RP   SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S).
RX   PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8;
RA   Hillman R.T., Green R.E., Brenner S.E.;
RT   "An unappreciated role for RNA surveillance.";
RL   Genome Biol. 5:R8.1-R8.16(2004).
RN   [7]
RP   LACK OF INVOLVEMENT IN SPERMATOGENIC FAILURE.
RX   PubMed=19246359; DOI=10.1056/NEJMoa0806218;
RA   Luddi A., Margollicci M., Gambera L., Serafini F., Cioni M.,
RA   De Leo V., Balestri P., Piomboni P.;
RT   "Spermatogenesis in a man with complete deletion of USP9Y.";
RL   N. Engl. J. Med. 360:881-885(2009).
CC   -!- FUNCTION: May function as a ubiquitin-protein or polyubiquitin
CC       hydrolase involved both in the processing of ubiquitin precursors
CC       and of ubiquitinated proteins. May therefore play an important
CC       regulatory role at the level of protein turnover by preventing
CC       degradation of proteins through the removal of conjugated
CC       ubiquitin. Essential component of TGF-beta/BMP signaling cascade.
CC       Deubiquitinates monoubiquitinated SMAD4, opposing the activity of
CC       E3 ubiquitin-protein ligase TRIM33. Monoubiquitination of SMAD4
CC       hampers its ability to form a stable complex with activated
CC       SMAD2/3 resulting in inhibition of TGF-beta/BMP signaling cascade.
CC       Deubiquitination of SMAD4 by USP9X re-empowers its competence to
CC       mediate TGF-beta signaling (By similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: Thiol-dependent hydrolysis of ester,
CC       thioester, amide, peptide and isopeptide bonds formed by the C-
CC       terminal Gly of ubiquitin (a 76-residue protein attached to
CC       proteins as an intracellular targeting signal).
CC   -!- SUBUNIT: Interacts with SMAD4. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=Long;
CC         IsoId=O00507-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=O00507-2; Sequence=VSP_005272;
CC         Note=May be produced at very low levels due to a premature stop
CC         codon in the mRNA, leading to nonsense-mediated mRNA decay.;
CC   -!- TISSUE SPECIFICITY: Widely expressed in embryonic and adult
CC       tissues.
CC   -!- DISEASE: Note=USP9Y is located in the 'azoospermia factor a'
CC       (AZFa) region on chromosome Y which is deleted in Sertoli cell-
CC       only syndrome. This is an infertility disorder in which no germ
CC       cells are visible in seminiferous tubules leading to azoospermia.
CC       However, AZFa deletions resulting in complete loss of USP9Y have
CC       also been found in normospermic men (PubMed:19246359).
CC       {ECO:0000269|PubMed:19246359}.
CC   -!- DISEASE: Spermatogenic failure Y-linked 2 (SPGFY2) [MIM:415000]: A
CC       disorder resulting in the absence (azoospermia) or reduction
CC       (oligozoospermia) of sperm in the semen, leading to male
CC       infertility. {ECO:0000269|PubMed:10581029}. Note=The disease may
CC       be caused by mutations affecting the gene represented in this
CC       entry. The role of USP9Y in spermatogenesis failure is uncertain
CC       (PubMed:19246359). A 4-bp deletion in a splice-donor site, causing
CC       exon skipping and protein truncation has been observed in non-
CC       obstructive azoospermia (PubMed:10581029). However, complete USP9Y
CC       deletion has been detected in individuals with no spermatogenic
CC       defects (PubMed:19246359). {ECO:0000269|PubMed:10581029,
CC       ECO:0000269|PubMed:19246359}.
CC   -!- SIMILARITY: Belongs to the peptidase C19 family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF000986; AAC51833.1; -; mRNA.
DR   EMBL; Y13618; CAA73940.1; -; mRNA.
DR   EMBL; Y13619; CAA73941.1; -; mRNA.
DR   EMBL; AC002531; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS14781.1; -. [O00507-1]
DR   RefSeq; NP_004645.2; NM_004654.3. [O00507-1]
DR   UniGene; Hs.598540; -.
DR   ProteinModelPortal; O00507; -.
DR   BioGrid; 113892; 13.
DR   IntAct; O00507; 6.
DR   MINT; MINT-7230431; -.
DR   STRING; 9606.ENSP00000342812; -.
DR   MEROPS; C19.028; -.
DR   iPTMnet; O00507; -.
DR   PhosphoSitePlus; O00507; -.
DR   BioMuta; USP9Y; -.
DR   EPD; O00507; -.
DR   MaxQB; O00507; -.
DR   PaxDb; O00507; -.
DR   PeptideAtlas; O00507; -.
DR   PRIDE; O00507; -.
DR   Ensembl; ENST00000338981; ENSP00000342812; ENSG00000114374. [O00507-1]
DR   GeneID; 8287; -.
DR   KEGG; hsa:8287; -.
DR   UCSC; uc004fst.2; human. [O00507-1]
DR   CTD; 8287; -.
DR   DisGeNET; 8287; -.
DR   GeneCards; USP9Y; -.
DR   GeneReviews; USP9Y; -.
DR   HGNC; HGNC:12633; USP9Y.
DR   HPA; HPA057687; -.
DR   MalaCards; USP9Y; -.
DR   MIM; 400005; gene.
DR   MIM; 415000; phenotype.
DR   neXtProt; NX_O00507; -.
DR   OpenTargets; ENSG00000114374; -.
DR   Orphanet; 1646; Partial chromosome Y deletion.
DR   PharmGKB; PA37258; -.
DR   eggNOG; KOG1866; Eukaryota.
DR   eggNOG; COG5077; LUCA.
DR   GeneTree; ENSGT00760000119158; -.
DR   HOGENOM; HOG000231283; -.
DR   HOVERGEN; HBG073749; -.
DR   InParanoid; O00507; -.
DR   KO; K11840; -.
DR   OMA; NSINCAR; -.
DR   OrthoDB; EOG091G0069; -.
DR   PhylomeDB; O00507; -.
DR   TreeFam; TF323966; -.
DR   GeneWiki; USP9Y; -.
DR   GenomeRNAi; 8287; -.
DR   PRO; PR:O00507; -.
DR   Proteomes; UP000005640; Chromosome Y.
DR   Bgee; ENSG00000114374; -.
DR   CleanEx; HS_USP10; -.
DR   CleanEx; HS_USP9Y; -.
DR   ExpressionAtlas; O00507; baseline and differential.
DR   Genevisible; O00507; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0070410; F:co-SMAD binding; ISS:BHF-UCL.
DR   GO; GO:0008234; F:cysteine-type peptidase activity; TAS:ProtInc.
DR   GO; GO:0004843; F:thiol-dependent ubiquitin-specific protease activity; TAS:ProtInc.
DR   GO; GO:0030509; P:BMP signaling pathway; ISS:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0016579; P:protein deubiquitination; ISS:UniProtKB.
DR   GO; GO:0007283; P:spermatogenesis; TAS:ProtInc.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IEA:InterPro.
DR   Gene3D; 1.25.10.10; -; 1.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR001394; Peptidase_C19_UCH.
DR   InterPro; IPR018200; USP_CS.
DR   InterPro; IPR028889; USP_dom.
DR   Pfam; PF00443; UCH; 1.
DR   SUPFAM; SSF48371; SSF48371; 3.
DR   PROSITE; PS00972; USP_1; 1.
DR   PROSITE; PS00973; USP_2; 1.
DR   PROSITE; PS50235; USP_3; 1.
PE   2: Evidence at transcript level;
KW   Alternative splicing; Complete proteome; Cytoplasm; Hydrolase;
KW   Phosphoprotein; Polymorphism; Protease; Reference proteome;
KW   Thiol protease; Ubl conjugation pathway.
FT   CHAIN         1   2555       Probable ubiquitin carboxyl-terminal
FT                                hydrolase FAF-Y.
FT                                /FTId=PRO_0000080690.
FT   DOMAIN     1559   1958       USP.
FT   ACT_SITE   1568   1568       Nucleophile. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10092, ECO:0000255|PROSITE-
FT                                ProRule:PRU10093}.
FT   ACT_SITE   1881   1881       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10092, ECO:0000255|PROSITE-
FT                                ProRule:PRU10093}.
FT   MOD_RES     589    589       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q93008}.
FT   MOD_RES     591    591       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q93008}.
FT   MOD_RES    2444   2444       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q93008}.
FT   MOD_RES    2541   2541       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q93008}.
FT   MOD_RES    2548   2548       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q93008}.
FT   VAR_SEQ    2071   2555       Missing (in isoform Short).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_005272.
FT   VARIANT      65     65       E -> D (in dbSNP:rs7067496).
FT                                /FTId=VAR_055350.
FT   VARIANT     211    211       R -> C (in dbSNP:rs2032596).
FT                                /FTId=VAR_055351.
FT   VARIANT    1035   1035       P -> S (in dbSNP:rs20319).
FT                                /FTId=VAR_029328.
FT   VARIANT    1060   1060       A -> T (in dbSNP:rs20320).
FT                                {ECO:0000269|PubMed:9384609}.
FT                                /FTId=VAR_016194.
FT   VARIANT    1705   1705       A -> S (in dbSNP:rs2032606).
FT                                /FTId=VAR_055352.
FT   CONFLICT    206    206       D -> E (in Ref. 3; CAA73940/CAA73941).
FT                                {ECO:0000305}.
FT   CONFLICT    282    282       I -> M (in Ref. 2; AAC51833).
FT                                {ECO:0000305}.
FT   CONFLICT    524    524       D -> Y (in Ref. 2; AAC51833).
FT                                {ECO:0000305}.
FT   CONFLICT    542    542       S -> A (in Ref. 2; AAC51833).
FT                                {ECO:0000305}.
FT   CONFLICT    666    666       L -> V (in Ref. 2; AAC51833).
FT                                {ECO:0000305}.
FT   CONFLICT    883    883       R -> C (in Ref. 3; CAA73940/CAA73941).
FT                                {ECO:0000305}.
FT   CONFLICT    907    907       S -> F (in Ref. 3; CAA73940/CAA73941).
FT                                {ECO:0000305}.
FT   CONFLICT    946    946       D -> N (in Ref. 3; CAA73940/CAA73941).
FT                                {ECO:0000305}.
FT   CONFLICT   1002   1002       E -> K (in Ref. 3; CAA73940/CAA73941).
FT                                {ECO:0000305}.
FT   CONFLICT   1017   1017       R -> K (in Ref. 3; CAA73940/CAA73941).
FT                                {ECO:0000305}.
FT   CONFLICT   1025   1027       VAD -> FAN (in Ref. 3; CAA73940/
FT                                CAA73941). {ECO:0000305}.
FT   CONFLICT   1038   1039       RD -> KN (in Ref. 3; CAA73940/CAA73941).
FT                                {ECO:0000305}.
FT   CONFLICT   1067   1067       K -> N (in Ref. 3; CAA73940/CAA73941).
FT                                {ECO:0000305}.
FT   CONFLICT   1258   1258       V -> F (in Ref. 3; CAA73940/CAA73941).
FT                                {ECO:0000305}.
FT   CONFLICT   1733   1733       Y -> F (in Ref. 3; CAA73940/CAA73941).
FT                                {ECO:0000305}.
FT   CONFLICT   1953   1953       L -> P (in Ref. 3; CAA73940/CAA73941).
FT                                {ECO:0000305}.
FT   CONFLICT   2086   2086       R -> G (in Ref. 2; AAC51833).
FT                                {ECO:0000305}.
SQ   SEQUENCE   2555 AA;  291077 MW;  421D47D5899F4415 CRC64;
     MTAITHGSPV GGNDSQGQVL DGQSQHLFQQ NQTSSPDSSN ENSVATPPPE EQGQGDAPPQ
     HEDEEPAFPH TELANLDDMI NRPRWVVPVL PKGELEVLLE AAIDLSVKGL DVKSEACQRF
     FRDGLTISFT KILMDEAVSG WKFEIHRCII NNTHRLVELC VAKLSQDWFP LLELLAMALN
     PHCKFHIYNG TRPCELISSN AQLPEDELFA RSSDPRSPKG WLVDLINKFG TLNGFQILHD
     RFFNGSALNI QIIAALIKPF GQCYEFLSQH TLKKYFIPVI EIVPHLLENL TDEELKKEAK
     NEAKNDALSM IIKSLKNLAS RISGQDETIK NLEIFRLKMI LRLLQISSFN GKMNALNEIN
     KVISSVSYYT HRHSNPEEEE WLTAERMAEW IQQNNILSIV LQDSLHQPQY VEKLEKILRF
     VIKEKALTLQ DLDNIWAAQA GKHEAIVKNV HDLLAKLAWD FSPGQLDHLF DCFKASWTNA
     SKKQREKLLE LIRRLAEDDK DGVMAHKVLN LLWNLAQSDD VPVDIMDLAL SAHIKILDYS
     CSQDRDAQKI QWIDHFIEEL RTNDKWVIPA LKQIREICSL FGEASQNLSQ TQRSPHIFYR
     HDLINQLQQN HALVTLVAEN LATYMNSIRL YAGDHEDYDP QTVRLGSRYS HVQEVQERLN
     FLRFLLKDGQ LWLCAPQAKQ IWKCLAENAV YLCDREACFK WYSKLMGDEP DLDPDINKDF
     FESNVLQLDP SLLTENGMKC FERFFKAVNC RERKLIAKRR SYMMDDLELI GLDYLWRVVI
     QSSDEIANRA IDLLKEIYTN LGPRLKANQV VIHEDFIQSC FDRLKASYDT LCVFDGDKNS
     INCARQEAIR MVRVLTVIKE YINECDSDYH KERMILPMSR AFRGKHLSLI VRFPNQGRQV
     DELDIWSHTN DTIGSVRRCI VNRIKANVAH KKIELFVGGE LIDSEDDRKL IGQLNLKDKS
     LITAKLTQIN FNMPSSPDSS SDSSTASPGN HRNHYNDGPN LEVESCLPGV IMSVHPRYIS
     FLWQVADLGS NLNMPPLRDG ARVLMKLMPP DRTAVEKLRA VCLDHAKLGE GKLSPPLDSL
     FFGPSASQVL YLTEVVYALL MPAGVPLTDG SSDFQVHFLK SGGLPLVLSM LIRNNFLPNT
     DMETRRGAYL NALKIAKLLL TAIGYGHVRA VAEACQPVVD GTDPITQINQ VTHDQAVVLQ
     SALQSIPNPS SECVLRNESI LLAQEISNEA SRYMPDICVI RAIQKIIWAS ACGALGLVFS
     PNEEITKIYQ MTTNGSNKLE VEDEQVCCEA LEVMTLCFAL LPTALDALSK EKAWQTFIID
     LLLHCPSKTV RQLAQEQFFL MCTRCCMGHR PLLFFITLLF TILGSTAREK GKYSGDYFTL
     LRHLLNYAYN GNINIPNAEV LLVSEIDWLK RIRDNVKNTG ETGVEEPILE GHLGVTKELL
     AFQTSEKKYH FGCEKGGANL IKELIDDFIF PASKVYLQYL RSGELPAEQA IPVCSSPVTI
     NAGFELLVAL AIGCVRNLKQ IVDCLTEMYY MGTAITTCEA LTEWEYLPPV GPRPPKGFVG
     LKNAGATCYM NSVIQQLYMI PSIRNSILAI EGTGSDLHDD MFGDEKQDSE SNVDPRDDVF
     GYPHQFEDKP ALSKTEDRKE YNIGVLRHLQ VIFGHLAASQ LQYYVPRGFW KQFRLWGEPV
     NLREQHDALE FFNSLVDSLD EALKALGHPA ILSKVLGGSF ADQKICQGCP HRYECEESFT
     TLNVDIRNHQ NLLDSLEQYI KGDLLEGANA YHCEKCDKKV DTVKRLLIKK LPRVLAIQLK
     RFDYDWEREC AIKFNDYFEF PRELDMGPYT VAGVANLERD NVNSENELIE QKEQSDNETA
     GGTKYRLVGV LVHSGQASGG HYYSYIIQRN GKDDQTDHWY KFDDGDVTEC KMDDDEEMKN
     QCFGGEYMGE VFDHMMKRMS YRRQKRWWNA YILFYEQMDM IDEDDEMIRY ISELTIARPH
     QIIMSPAIER SVRKQNVKFM HNRLQYSLEY FQFVKKLLTC NGVYLNPAPG QDYLLPEAEE
     ITMISIQLAA RFLFTTGFHT KKIVRGPASD WYDALCVLLR HSKNVRFWFT HNVLFNVSNR
     FSEYLLECPS AEVRGAFAKL IVFIAHFSLQ DGSCPSPFAS PGPSSQACDN LSLSDHLLRA
     TLNLLRREVS EHGHHLQQYF NLFVMYANLG VAEKTQLLKL NVPATFMLVS LDEGPGPPIK
     YQYAELGKLY SVVSQLIRCC NVSSTMQSSI NGNPPLPNPF GDLNLSQPIM PIQQNVLDIL
     FVRTSYVKKI IEDCSNSEDT IKLLRFCSWE NPQFSSTVLS ELLWQVAYSY TYELRPYLDL
     LFQILLIEDS WQTHRIHNAL KGIPDDRDGL FDTIQRSKNH YQKRAYQCIK CMVALFSSCP
     VAYQILQGNG DLKRKWTWAV EWLGDELERR PYTGNPQYSY NNWSPPVQSN ETANGYFLER
     SHSARMTLAK ACELCPEEEP DDQDAPDEHE PSPSEDAPLY PHSPASQYQQ NNHVHGQPYT
     GPAAHHLNNP QKTGQRTQEN YEGNEEVSSP QMKDQ
//
